Targeting the somatostatin receptor in pituitary and neuroendocrine tumors

Author： Veenstra Marije J de Herder Wouter W Feelders Richard A Hofland Leo J

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.17, Iss.11, 2013-11, pp. : 1329-1343

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The somatostatin receptor subtype 5 in neuroendocrine tumours

By van der Hoek Joost Lamberts Steven WJ Hofland Leo J

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 3, 2010-03 ,pp. : 385-399

Informa Healthcare

Access to resources Recommend Favorite

A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors

By Reubi J.C. Schaer J.-C. Waser B. Hoeger C. Rivier J.

European Journal of Pharmacology, Vol. 345, Iss. 1, 1998-03 ,pp. : 103-110

Elsevier

Access to resources Recommend Favorite

Somatostatin: the neuroendocrine story

By Gillies G.

Trends in Pharmacological Sciences, Vol. 18, Iss. 3, 1997-03 ,pp. : 87-95

Elsevier

Access to resources Recommend Favorite

Neuroendocrine Tumors

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 7, Iss. 7, 2009-07 ,pp. : 712-712

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Erratum: Okuwaki K, Kida M, Mikami T, Yamauchi H, Imaizumi H, Miyazawa S, Iwai T, Takezawa M, Saegusa M, Watanabe M and Koizumi W. Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes. Cancer. 2013;119:4094-102.

Cancer, Vol. 120, Iss. 8, 2014-04 ,pp. : 1283-1285

Blackwell Publishing

Access to resources Recommend Favorite